Ab therapy of AML: native anti-CD33 Ab and drug conjugates.
MAb have become an important treatment modality in cancer therapy.Genetically engineered chimeric and humanized Ab have demonstrated activity against a variety of tumors. While the humanized anti-CD33MAb lintuzumab has only modest single-agent activity against overt AML, it can eliminate minimal residual disease detectable by reverse transcription-PCR in acute promyelocytic leukemia. Targeted chemotherapy with the anti−CD33−calicheamicin construct gemtuzumab ozogamicin has produced remissions in patients with relapsed AML and appears promising when used in combination with standard chemotherapy in the treatment of newly diagnosed AML.
Jurcic
J G
JG
Memorial Sloan-Kettering Cancer Center, Department of Medicine, New York, New York, USA. jurcicj@mskcc.org
D000617:Aminoglycosides / Q000008:administration & dosage / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use; D015703:Antigens, CD / Q000008:administration & dosage / Q000627:therapeutic use*; D015214:Antigens, Differentiation, Myelomonocytic / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000079982:Gemtuzumab; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000628:therapy*; D063268:Sialic Acid Binding Ig-like Lectin 3
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; C571163:CD33 protein, human; D063268:Sialic Acid Binding Ig-like Lectin 3; D000079982:Gemtuzumab; C477390:lintuzumab